- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
California Regulator Criticizes Aetna Rate Increase As 'Unreasonable'
A California insurance regulator ruled that an Aetna Inc. health-insurance rate increase was “unreasonable,” in the latest salvo of a long-running debate in the state over the cost of coverage.
The announcement by California Insurance Commissioner Dave Jones focused on a boost that affects small-group plans and became effective April 1. It was the first time the department has officially used a new ability, granted under a state law that took effect at the beginning of 2011, to call out rates as unreasonable.
But the regulator has been jawboning carriers over their rate filings, and he said in all previous cases insurers have agreed to modify their rate hike proposals before they were formally declared unreasonable. Most recently, the department said that WellPoint Inc.’s Anthem Blue Cross and Blue Shield of California both agreed to make changes to rate filings for the individual market.
Read the full story: http://hcp.lv/HrhhXw
Source: The Wall Street Journal
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
